By Jean-Paul McDonald
Farms.com
Merck Animal Health, also known as MSD Animal Health outside of North America, has launched a game-changing swine flu vaccine called SEQUIVITY IAV-S NA (Swine Influenza Vaccine, N1 and N2, RNA Particle). This revolutionary vaccine is designed to protect pigs against the H1N1, H1N2, and H3N2 influenza strains, marking a significant advancement in swine health.
What sets SEQUIVITY IAV-S NA apart is its unique approach. This commercial vaccine relies solely on the influenza neuraminidase (NA) surface antigen to provide immunity. The NA RNA particles, a critical component of the vaccine, are produced using Merck Animal Health's state-of-the-art SEQUIVITY platform technology, which has a track record of effectively targeting swine pathogens, both established and emerging.
Dr. Channing Sebo-Decker, a swine technical services veterinarian at Merck Animal Health, expressed enthusiasm for this innovative vaccine. He emphasized that the SEQUIVITY IAV-S NA vaccine represents a significant technological leap and a valuable tool for swine flu control programs.